UNC 2881 structure
|
Common Name | UNC 2881 | ||
|---|---|---|---|---|
| CAS Number | 1493764-08-1 | Molecular Weight | 463.575 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C25H33N7O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of UNC 2881UNC2881 is a potent and specific Mer kinase inhibitor; inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. IC50 value: 22 nM [1]Target: Mer kinase inhibitorTreatment with UNC2281 is also sufficient to block EGF-mediated stimulation of a chimeric receptor containing the intracellular domain of Mer fused to the extracellular domain of EGFR. In addition, UNC2881 potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhibitors may have utility for prevention and/or treatment of pathologic thrombosis. |
| Name | 5-Pyrimidinecarboxamide, 2-(butylamino)-4-[(trans-4-hydroxycyclohexyl)amino]-N-[[4-(1H-imidazol-1-yl)phenyl]methyl]- |
|---|---|
| Synonym | More Synonyms |
| Description | UNC2881 is a potent and specific Mer kinase inhibitor; inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. IC50 value: 22 nM [1]Target: Mer kinase inhibitorTreatment with UNC2281 is also sufficient to block EGF-mediated stimulation of a chimeric receptor containing the intracellular domain of Mer fused to the extracellular domain of EGFR. In addition, UNC2881 potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhibitors may have utility for prevention and/or treatment of pathologic thrombosis. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C25H33N7O2 |
| Molecular Weight | 463.575 |
| Exact Mass | 463.269562 |
| PSA | 116.99000 |
| LogP | 3.03 |
| Index of Refraction | 1.666 |
| Storage condition | -20℃ |
| Water Solubility | Insuluble (1.7E-3 g/L) (25 ºC) |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
| 5-Pyrimidinecarboxamide, 2-(butylamino)-4-[(trans-4-hydroxycyclohexyl)amino]-N-[[4-(1H-imidazol-1-yl)phenyl]methyl]- |
| 2-(Butylamino)-4-[(trans-4-hydroxycyclohexyl)amino]-N-[4-(1H-imidazol-1-yl)benzyl]-5-pyrimidinecarboxamide |
| UNC2881 |